Multiparametric MRI-based Dosimetric Parameters Best Predict Short-term Time Course of PSA After Iodine 125 Permanent Prostate Implantation for Localized Prostate Cancer

2012 ◽  
Vol 84 (3) ◽  
pp. S366
Author(s):  
M. Quivrin ◽  
R. Loffroy ◽  
C. Mirjolet ◽  
D. Sottier ◽  
A. Cueff ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Time Course ◽  
Multiparametric Mri ◽  
Localized Prostate Cancer ◽  
Short Term ◽  
Iodine 125

PO-0244 HDR brachytherapy monotherapy with 2 x 13.5 Gy for localized prostate cancer: short term follow up

2021 ◽  
Vol 158 ◽  
pp. S203-S204
Author(s):  
M. Christianen ◽  
K. De Vries ◽  
P. Jansen ◽  
L. Luthart ◽  
I. Kolkman-Deurloo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Localized Prostate Cancer ◽  
Hdr Brachytherapy ◽  
Short Term

scholarly journals Men’s experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study

2021 ◽  
Author(s):  
E. Sutton ◽  
◽  
J. A. Lane ◽  
M. Davis ◽  
E. I. Walsh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
External Beam Radiotherapy ◽  
Qualitative Interviews ◽  
Well Being ◽  
Localized Prostate Cancer ◽  
Short Term ◽  
Age Related ◽  
Qualitative Interview Study ◽  
Long Term Treatment

Abstract Purpose To investigate men’s experiences of receiving external-beam radiotherapy (EBRT) with neoadjuvant Androgen Deprivation Therapy (ADT) for localized prostate cancer (LPCa) in the ProtecT trial. Methods A longitudinal qualitative interview study was embedded in the ProtecT RCT. Sixteen men with clinically LPCa who underwent EBRT in ProtecT were purposively sampled to include a range of socio-demographic and clinical characteristics. They participated in serial in-depth qualitative interviews for up to 8 years post-treatment, exploring experiences of treatment and its side effects over time. Results Men experienced bowel, sexual, and urinary side effects, mostly in the short term but some persisted and were bothersome. Most men downplayed the impacts, voicing expectations of age-related decline, and normalizing these changes. There was some reticence to seek help, with men prioritizing their relationships and overall health and well-being over returning to pretreatment levels of function. Some unmet needs with regard to information about treatment schedules and side effects were reported, particularly among men with continuing functional symptoms. Conclusions These findings reinforce the importance of providing universal clear, concise, and timely information and supportive resources in the short term, and more targeted and detailed information and care in the longer term to maintain and improve treatment experiences for men undergoing EBRT.

scholarly journals How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?

Cancer ◽  
2010 ◽  
Vol 116 (23) ◽  
pp. 5391-5399 ◽  
Author(s):  
Claire F. Snyder ◽  
Kevin D. Frick ◽  
Amanda L. Blackford ◽  
Robert J. Herbert ◽  
Bridget A. Neville ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Initial Treatment ◽  
Treatment Choice ◽  
Localized Prostate Cancer ◽  
Short Term

scholarly journals Relationship between sexual function and prostate-specific antigen bounce after iodine-125 permanent implant brachytherapy for localized prostate cancer

2014 ◽  
Vol 21 (7) ◽  
pp. 658-663 ◽  
Author(s):  
Kiyoaki Nishihara ◽  
Makoto Nakiri ◽  
Katsuaki Chikui ◽  
Shigetaka Suekane ◽  
Kei Matsuoka ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Sexual Function ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Localized Prostate Cancer ◽  
Iodine 125 ◽  
Permanent Implant

scholarly journals Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer–A Pilot Study

2020 ◽  
Vol 27 (10) ◽  
pp. 1432-1439 ◽  
Author(s):  
Fiona M. Fennessy ◽  
Andriy Fedorov ◽  
Mark G. Vangel ◽  
Robert V. Mulkern ◽  
Maria Tretiakova ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pilot Study ◽  
Neoadjuvant Therapy ◽  
Multiparametric Mri ◽  
Localized Prostate Cancer

scholarly journals Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer

2019 ◽  
Vol 47 (3) ◽  
pp. 665-673 ◽  
Author(s):  
Otto Ettala ◽  
Simona Malaspina ◽  
Terhi Tuokkola ◽  
Pauliina Luoto ◽  
Eliisa Löyttyniemi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Androgen Deprivation Therapy ◽  
Time Course ◽  
Specific Antigen ◽  
Androgen Deprivation ◽  
Short Term ◽  
Psma Pet ◽  
Treatment Naïve

Abstract Purpose Based on in vitro studies, it is known that androgen deprivation therapy (ADT) increases prostate-specific membrane antigen (PSMA) expression. Therefore, we hypothesised that ADT improves the performance of PSMA-PET imaging in primary staging of prostate cancer. The purpose of the study was to demonstrate the time course effect of ADT on PSMA uptake in different types of metastatic lesions evaluated with 68Ga-PSMA-11 PET/MRI. Methods Nine men with treatment-naïve prostate cancer were enrolled to a prospective, registered (NCT03313726) clinical trial. A 68Ga-PSMA-11 PET/MRI was performed once before and 3 times post-ADT (degarelix, Firmagon). Change of maximum standardised uptake values (SUVmax) in prostate, lymph nodes, bone metastases, and physiologically PSMA-avid organs were evaluated in a time frame of 1–8 weeks. Results All patients reached castration levels within 10 days, and 50% decrease in prostate-specific antigen (PSA) concentration was observed 14 days post-ADT. A heterogeneous increase in PSMA uptake was observed 3 to 4 weeks post-ADT. This phenomenon was definitively more evident in bone metastases: 13 (57%) of the metastasis, with a mean (range) SUVmax increase of 77% (8–238%). In one patient, already having bone metastases at baseline, three new bone metastases were observed post-ADT. Of lesions with reduced SUVmax, none disappeared. Conclusions Both in patient and region level, increase in PSMA uptake post-ADT is heterogenous and is seen most evidently in bone metastases. Preliminary results on a small cohort of patients suggest the clinical impact of ADT on improving the performance of 68Ga-PSMA PET in staging seems to be minor. However, the optimal imaging time point might be 3 to 4 weeks post-ADT. Since none of the metastases with decreasing SUVmax disappeared, it seems that short-term usage of ADT does not interfere with the interpretation of 68Ga-PSMA PET. Trial registration NCT03313726, registered 18 October 2017; EUDRA-CT, 2017-002345-29.

scholarly journals Response of leukocyte to iodine-125 permanent prostate seed implantation predict PSA failure in patients with localized prostate cancer

2020 ◽  
Vol 19 ◽  
pp. e248-e249
Author(s):  
Y. Ozawa ◽  
N. Santo ◽  
Y. Yagi ◽  
T. Nishiyama ◽  
T. Yokoi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Localized Prostate Cancer ◽  
Seed Implantation ◽  
Psa Failure ◽  
Iodine 125
Sign in / Sign up

Export Citation Format

Share Document